<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE article
  PUBLIC "-//NLM//DTD Journal Publishing DTD v2.3 20070202//EN" "journalpublishing.dtd">
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" article-type="research-article">
<front>
<journal-meta>
<journal-id journal-id-type="publisher-id">JCP</journal-id>
<journal-id journal-id-type="hwp">jclinpharm</journal-id>
<journal-id journal-id-type="nlm-ta">J Clin Pharmacol</journal-id>
<journal-title>The Journal of Clinical Pharmacology</journal-title>
<issn pub-type="ppub">0091-2700</issn>
<issn pub-type="epub">1552-4604</issn>
<publisher>
<publisher-name>SAGE Publications</publisher-name>
<publisher-loc>Sage CA: Los Angeles, CA</publisher-loc>
</publisher>
</journal-meta>
<article-meta>
<article-id pub-id-type="doi">10.1177/0091270010388648</article-id>
<article-id pub-id-type="publisher-id">10.1177_0091270010388648</article-id>
<article-categories>
<subj-group subj-group-type="heading">
<subject>Pharmacokinetics and Pharmacodynamics</subject>
</subj-group>
</article-categories>
<title-group>
<article-title>Fixed Dosing Versus Body Size–Based Dosing of Therapeutic Peptides and Proteins in Adults</article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author">
<name><surname>Zhang</surname><given-names>Shuzhong</given-names></name>
<degrees>PhD</degrees>
</contrib>
<contrib contrib-type="author">
<name><surname>Shi</surname><given-names>Rong</given-names></name>
<degrees>MS</degrees>
</contrib>
<contrib contrib-type="author">
<name><surname>Li</surname><given-names>Chunze</given-names></name>
<degrees>PhD</degrees>
</contrib>
<contrib contrib-type="author">
<name><surname>Parivar</surname><given-names>Kourosh</given-names></name>
<degrees>MS</degrees>
</contrib>
<contrib contrib-type="author" corresp="yes">
<name><surname>Wang</surname><given-names>Diane D.</given-names></name>
<degrees>PhD</degrees>
</contrib>
</contrib-group>
<aff id="aff1-0091270010388648">Pfizer Oncology, San Diego, California (Dr Zhang, Dr Li, Dr Parivar, Dr Wang)</aff>
<aff id="aff2-0091270010388648">Department of Pharmaceutics, University of Florida, Gainesville (Ms Shi)</aff>
<author-notes>
<corresp id="corresp1-0091270010388648">Diane D. Wang, PhD, Pfizer Oncology, 10646 Science Center Dr, San Diego, CA 92121; e-mail: <email>diane.wang@pfizer.com</email>.</corresp>
</author-notes>
<pub-date pub-type="epub-ppub">
<month>1</month>
<year>2012</year>
</pub-date>
<volume>52</volume>
<issue>1</issue>
<fpage>18</fpage>
<lpage>28</lpage>
<history>
<date date-type="received">
<day>14</day>
<month>7</month>
<year>2010</year>
</date>
<date date-type="accepted">
<day>3</day>
<month>10</month>
<year>2010</year>
</date>
</history>
<permissions>
<copyright-statement>© 2012 American College of Clinical Pharmacology, Inc.</copyright-statement>
<copyright-year>2012</copyright-year>
<copyright-holder content-type="society">American College of Clinical Pharmacology, Inc.</copyright-holder>
</permissions>
<abstract>
<p>Therapeutic biologics are often administered based on body size. A previous study has found that fixed dosing performs similarly to body size–based dosing in reducing intersubject variability in drug exposure across the mAbs studied. This study extended this evaluation to other therapeutic proteins and peptides. Eighteen therapeutic proteins and peptides with published population pharmacokinetic (PK) and/or pharmacodynamic (PD) models were selected for dosing approach evaluation. The relationships between body size and drug exposure (and PD end point when available) were evaluated, and simulation studies were conducted to compare the performance of the 2 dosing approaches. The results showed that fixed dosing performed better for 12 of 18 selected biologics in terms of reducing intersubject variability in exposure at both population and individual levels, whereas body size–based dosing performed better for the other 6 molecules. This result is consistent with the findings for mAbs. Therefore, fixed dosing is recommended for first-in-human studies of proteins and peptides along with mAbs. The final dosing approach for phase 3 studies should be determined based on a full assessment of body size effect on PK/PD when data are available and the therapeutic window of the drug.</p>
</abstract>
<kwd-group>
<kwd>Fixed dosing</kwd>
<kwd>body size–based dosing</kwd>
<kwd>body weight</kwd>
<kwd>body surface area</kwd>
<kwd>biologics</kwd>
<kwd>monoclonal antibodies</kwd>
<kwd>population pharmacokinetics</kwd>
<kwd>pharmacodynamics</kwd>
<kwd>protein</kwd>
<kwd>peptide</kwd>
</kwd-group>
</article-meta>
</front>
<body>
<p>In contrast to small-molecule drugs, which are commonly dosed with fixed doses, therapeutic biologics are often administered based on patients’ body size, such as body weight (BW) and body surface area (BSA). It has been generally perceived that dosing biologics based on patients’ body size would reduce interpatient variability in pharmacokinetics (PK) and/or pharmacodynamics (PD) and thereby optimize their therapeutic outcomes, based on the theory that patients with larger body size would have a larger volume of distribution and a higher elimination capacity.</p>
<p>The validity of the above perception, however, has recently been challenged for dosing of mAb therapeutics.<sup><xref ref-type="bibr" rid="bibr1-0091270010388648">1</xref></sup> Through simulation studies of 12 approved mAbs with published population PK and/or PD models, Wang et al<sup><xref ref-type="bibr" rid="bibr1-0091270010388648">1</xref></sup> compared the performance of fixed and body size–based dosing with regard to reducing intersubject PK and/or PD variability in adult patients. In contrast to the expectation that body size–based dosing should produce less intersubject variability, their results showed that fixed dosing performed similarly to body size–based dosing across the 12 mAbs evaluated, with fixed dosing being better for some mAbs (7 of 12) and body size–based dosing being better for the others (5 of 12). The study indicated that determination of body size as a significant covariate on clearance (CL) parameter does not necessarily justify body size–based dosing as a better approach than fixed dosing even when the only consideration is to reduce PK and/or PD variability, because simple body size correction as mg/kg or mg/m<sup>2</sup> could overcorrect the effect of body size on exposure. The determinant factor is the value of the exponent (α) when the effect of body size on CL is described by a power function, as shown in <xref ref-type="disp-formula" rid="disp-formula1-0091270010388648">equation (1)</xref>.</p>
<p><disp-formula id="disp-formula1-0091270010388648">
<label>(1)</label>
<mml:math display="block" id="math1-0091270010388648">
<mml:mrow>
<mml:mtext>CL</mml:mtext>
<mml:mo>=</mml:mo>
<mml:mtext>C</mml:mtext>
<mml:msub>
<mml:mtext>L</mml:mtext>
<mml:mrow>
<mml:mtext>typical</mml:mtext>
</mml:mrow>
</mml:msub>
<mml:mo>⋅</mml:mo>
<mml:msup>
<mml:mrow>
<mml:mo>(</mml:mo>
<mml:mfrac>
<mml:mrow>
<mml:mtext>body size</mml:mtext>
</mml:mrow>
<mml:mrow>
<mml:mtext>body siz</mml:mtext>
<mml:msub>
<mml:mtext>e</mml:mtext>
<mml:mrow>
<mml:mtext>typical</mml:mtext>
</mml:mrow>
</mml:msub>
</mml:mrow>
</mml:mfrac>
<mml:mo>)</mml:mo>
</mml:mrow>
<mml:mi>α</mml:mi>
</mml:msup>
<mml:mo>.</mml:mo>
</mml:mrow>
</mml:math>
<graphic alternate-form-of="disp-formula1-0091270010388648" xlink:href="10.1177_0091270010388648-eq1.tif"/>
</disp-formula></p>
<p>In terms of reducing intersubject variability in the area under the concentration-time curve (AUC), body size–based dosing would work the best when CL is body size proportional (α = 1), and fixed dosing would work the best when CL is not affected by body size (α = 0). The 2 dosing approaches would perform similarly when the α value is close to 0.5. Fixed dosing is expected to produce less variability in AUC when the α value is less than 0.5, and the opposite is true when α values are greater than 0.5 (<xref ref-type="fig" rid="fig1-0091270010388648">Figure 1</xref>).</p>
<fig id="fig1-0091270010388648" position="float">
<label>Figure 1.</label>
<caption>
<p>The percent difference of AUC for patients with extremely low body weight (BW; 40 kg, colored broken lines) and extremely high BW (140 kg, colored solid lines) from those for patients with a median BW of 75 kg as a function of the α values following a fixed (red) and a BW-based (green) dose, assuming <inline-formula id="inline-formula1-0091270010388648">
<mml:math display="inline" id="math2-0091270010388648">
<mml:mrow>
<mml:mtext>CL</mml:mtext>
<mml:mo>=</mml:mo>
<mml:mtext>C</mml:mtext>
<mml:msub>
<mml:mtext>L</mml:mtext>
<mml:mrow>
<mml:mtext>typical</mml:mtext>
</mml:mrow>
</mml:msub>
<mml:mo>⋅</mml:mo>
<mml:msup>
<mml:mrow>
<mml:mo>(</mml:mo>
<mml:mfrac>
<mml:mrow>
<mml:mtext>body size</mml:mtext>
</mml:mrow>
<mml:mrow>
<mml:mtext>body siz</mml:mtext>
<mml:msub>
<mml:mtext>e</mml:mtext>
<mml:mrow>
<mml:mtext>typical</mml:mtext>
</mml:mrow>
</mml:msub>
</mml:mrow>
</mml:mfrac>
<mml:mo>)</mml:mo>
</mml:mrow>
<mml:mi>α</mml:mi>
</mml:msup>
<mml:mo>.</mml:mo>
</mml:mrow>
</mml:math>
</inline-formula> The shaded area represents AUC values within 100% ± 20% of typical AUC. Reprinted from Wang et al<sup><xref ref-type="bibr" rid="bibr1-0091270010388648">1</xref></sup> with permission.</p>
</caption>
<graphic xlink:href="10.1177_0091270010388648-fig1.tif"/>
</fig>
<p>The contribution of body size effect to overall PK and/or PD intersubject variability was also evaluated, as many other factors, besides body size, could also contribute to the intersubject variability in PK and/or PD of a given drug. These factors include intrinsic factors (eg, age, gender, disease states, and genetic polymorphism) and environmental factors (eg, concomitant medication and smoking). Depending on the contribution of body size effect to the overall intersubject variability, body size–based dosing may or may not be necessary even when it significantly reduces intersubject variability in certain PK and/or PD parameters.</p>
<p>On the basis of the findings from this analysis, the authors recommended (1) using fixed dosing in first-in-human (FIH) adult studies for mAbs because of its convenience, better compliance, less risk for medical errors, and cost-effectiveness and (2) selecting the final dosing approach for phase 3 trials based on a full evaluation of the effect of body size and other influential factors on PK and PD of the study mAb along with its therapeutic window after sufficient data become available during drug development.<sup><xref ref-type="bibr" rid="bibr1-0091270010388648">1</xref></sup></p>
<p>As a continuation of the mAb study,<sup><xref ref-type="bibr" rid="bibr1-0091270010388648">1</xref></sup> the present study was set out to evaluate the clinical benefit of body size–based dosing for other therapeutic biologics—namely, therapeutic peptides and proteins. These biologics should be examined separately considering that the sources of the variability in exposure are likely to be different between mAbs and therapeutic peptides and proteins since they do not necessarily share the same distribution and elimination mechanisms. In contrast to mAbs, which usually share the same IgG structure with a molecular weight of ~150 kDa, therapeutic peptides and proteins comprise a much more diverse group of molecules. Large therapeutic proteins may share similar distribution and elimination mechanisms to mAbs. They are generally distributed via convection and eliminated via intracellular catabolism following fluid-phase or receptor-mediated endocytosis. However, mAbs differ from most therapeutic proteins in that a significant fraction of mAbs is protected from protein catabolism by FcRn-mediated recycling, whereas most of the therapeutic peptides and proteins do not have such protective mechanism with the exception of fusion proteins containing the Fc region of IgGs.<sup><xref ref-type="bibr" rid="bibr2-0091270010388648">2</xref>,<xref ref-type="bibr" rid="bibr3-0091270010388648">3</xref></sup> For smaller therapeutic peptides and proteins, depending on the molecular size and physicochemical properties (eg, charge and lipophilicity), renal excretion and diffusion into tissues may play an important role in their overall elimination and distribution mechanisms in addition to catabolism and convection.<sup><xref ref-type="bibr" rid="bibr2-0091270010388648">2</xref></sup> With increased amount of PK and PD information of this class of therapeutics accumulated in recent years, it is time to compare the clinical benefits of the 2 dosing approaches for therapeutic peptides and proteins. The objectives of the present study are therefore to (1) systemically evaluate the performance of fixed dosing and body size–based dosing for therapeutic peptides and proteins in adults and (2) recommend a dosing strategy for clinical trials conducted in adults at different stages of the development of therapeutic biologics other than mAbs.</p>
<sec id="section1-0091270010388648" sec-type="methods">
<title>Methods</title>
<sec id="section2-0091270010388648">
<title>Data Collection</title>
<p>Data used in this simulation study were collected from the population PK/PD studies of therapeutic peptides and proteins published in peer-reviewed journals. The selection criteria included the availability of population PK and/or PD models for adult patients or healthy volunteers and adequate assessment of the effect of body size on the PK (and/or PD) parameters.</p>
</sec>
<sec id="section3-0091270010388648">
<title>Population PK and PD Models</title>
<p>The population PK and/or PD models of the selected peptides and proteins (see <xref ref-type="table" rid="table1-0091270010388648">Table I</xref>) were obtained from published reports. General properties of these population PK and PD models and the effect of body size, such as BW or BSA, on the PK and/or PD parameters are summarized in <xref ref-type="table" rid="table2-0091270010388648">Table II</xref>.</p>
<table-wrap id="table1-0091270010388648" position="float">
<label>Table I</label>
<caption><p>Selected Therapeutic Peptides and Proteins and Their Dosing Approaches for Adult Patients</p></caption>
<graphic alternate-form-of="table1-0091270010388648" xlink:href="10.1177_0091270010388648-table1.tif"/>
<table>
<colgroup>
<col align="left"/>
<col align="left"/>
<col align="center"/>
<col align="center"/>
<col align="left"/>
<col align="left"/>
<col align="left"/>
</colgroup>
<thead>
<tr>
<th align="left">Generic Name</th>
<th align="center">Brand Name</th>
<th align="center">Approval Date</th>
<th align="center">Molecular Weight, Da</th>
<th align="center">Type</th>
<th align="center">Target</th>
<th align="center">Dosing Approach</th>
</tr>
</thead>
<tbody>
<tr>
<td>Abatacept</td>
<td>Orencia</td>
<td>2005</td>
<td>92300</td>
<td>Fusion protein</td>
<td>CD80/CD86</td>
<td>mg/kg</td>
</tr>
<tr>
<td>Daptomycin</td>
<td>Cubicin</td>
<td>2004</td>
<td>1620</td>
<td>Peptide</td>
<td>LTA synthesis</td>
<td>mg/kg</td>
</tr>
<tr>
<td>Darbepoetin alfa</td>
<td>Aranesp</td>
<td>2001</td>
<td>37100</td>
<td>Protein</td>
<td>EpoR</td>
<td>µg/kg</td>
</tr>
<tr>
<td>Degarelix</td>
<td>Firmagon</td>
<td>2008</td>
<td>1632</td>
<td>Peptide</td>
<td>GnRHR</td>
<td>mg</td>
</tr>
<tr>
<td>Emfilermin</td>
<td/>
<td>Discontinued</td>
<td>22007</td>
<td>Protein</td>
<td>LIFR</td>
<td>µg/kg</td>
</tr>
<tr>
<td>Enfuvirtide</td>
<td>Fuzeon</td>
<td>2003</td>
<td>4492</td>
<td>Peptide</td>
<td>gp41</td>
<td>mg</td>
</tr>
<tr>
<td>Erythropoietin alfa</td>
<td>EPOGEN</td>
<td>1989</td>
<td>30400</td>
<td>Protein</td>
<td>EpoR</td>
<td>Units/kg</td>
</tr>
<tr>
<td>Erythropoietin beta</td>
<td>NeoRecormon</td>
<td>1993</td>
<td>30000</td>
<td>Protein</td>
<td>EpoR</td>
<td>µg/kg</td>
</tr>
<tr>
<td>Etanercept</td>
<td>Enbrel</td>
<td>1999</td>
<td>150000</td>
<td>Fusion protein</td>
<td>TNF</td>
<td>mg</td>
</tr>
<tr>
<td>Hematide</td>
<td/>
<td>In development</td>
<td>NR</td>
<td>Pegylated peptide</td>
<td>EpoR</td>
<td>mg/kg</td>
</tr>
<tr>
<td>Lanreotide autogel</td>
<td>Somatuline</td>
<td>2007</td>
<td>1096</td>
<td>Peptide</td>
<td>IGF-1</td>
<td>mg</td>
</tr>
<tr>
<td>Octreotide acetate</td>
<td>Sandostatin</td>
<td>1988</td>
<td>1019</td>
<td>Peptide</td>
<td>SSTR2/5</td>
<td>µg</td>
</tr>
<tr>
<td>Onercept</td>
<td/>
<td>Discontinued</td>
<td>18000</td>
<td>Fusion protein</td>
<td>TNFR</td>
<td>mg/kg</td>
</tr>
<tr>
<td>PEG-interferon alpha-2b</td>
<td>PEG-Intron A</td>
<td>2001</td>
<td>19271</td>
<td>Protein</td>
<td>IFNAR1/2</td>
<td>µg/kg</td>
</tr>
<tr>
<td>Plitidepsin</td>
<td>Aplidin</td>
<td>2004</td>
<td>1110</td>
<td>Peptide</td>
<td>EGFR</td>
<td>mg/m<sup>2</sup></td>
</tr>
<tr>
<td>Recombinant factor VIIa</td>
<td>NovoSeven</td>
<td>1999</td>
<td>50000</td>
<td>Protein</td>
<td>TF</td>
<td>µg/kg</td>
</tr>
<tr>
<td>rhGH</td>
<td>Norditropin</td>
<td>1987</td>
<td>22000</td>
<td>Protein</td>
<td>GH receptor</td>
<td>mg/kg</td>
</tr>
<tr>
<td>u-hFSH</td>
<td>Metrodin HP</td>
<td>Discontinued</td>
<td>30000</td>
<td>Protein</td>
<td>FSH receptor</td>
<td>IU</td>
</tr>
</tbody>
</table>
<table-wrap-foot>
<fn id="table-fn1-0091270010388648">
<p>NR, not reported; rhGH, recombinant human growth hormone; u-hFSH, urinary human follicle-stimulating hormone.</p>
</fn>
</table-wrap-foot>
</table-wrap>
<table-wrap id="table2-0091270010388648" position="float">
<label>Table II</label>
<caption>
<p>Population Pharmacokinetics Models for the Selected Therapeutic Peptides and Proteins</p>
</caption>
<graphic alternate-form-of="table2-0091270010388648" xlink:href="10.1177_0091270010388648-table2.tif"/>
<table>
<colgroup>
<col align="left"/>
<col align="left"/>
<col align="char" char="."/>
<col align="left"/>
<col align="left"/>
<col align="left"/>
<col align="left"/>
<col align="char" char="."/>
<col align="char" char="."/>
<col align="char" char="."/>
</colgroup>
<thead>
<tr>
<th align="left">Generic Name</th>
<th align="center">Type</th>
<th align="center">Molecular Weight, Da</th>
<th align="center">Dosing</th>
<th align="center">Structure Model</th>
<th align="center">Body Size Covariates, Mean (SD or Range)</th>
<th align="center">Body Size Covariate Model</th>
<th align="center">n</th>
<th align="center">α on CL</th>
<th align="center">Reference</th>
</tr>
</thead>
<tbody>
<tr>
<td>Abatacept</td>
<td>Fusion protein</td>
<td>92300</td>
<td>mg/kg</td>
<td>2-CMT, linear</td>
<td>BW: 78.3 (21.0)</td>
<td>CL = CL0 + CL1 × (BW/78.3)</td>
<td>388</td>
<td>0.4<sup><xref ref-type="table-fn" rid="table-fn4-0091270010388648">a</xref></sup></td>
<td>5</td>
</tr>
<tr>
<td>Daptomycin</td>
<td>Peptide</td>
<td>1620</td>
<td>mg/kg</td>
<td>2-CMT linear</td>
<td>BW: 75.1 (48.2-152.8)</td>
<td>Q = 3.46 + 0.0593 × (BW − 75.1) V2 = 3.13 + 0.0458 × (BW − 75.1) × z<sup><xref ref-type="table-fn" rid="table-fn5-0091270010388648">b</xref></sup></td>
<td>282</td>
<td>0</td>
<td>8</td>
</tr>
<tr>
<td>Darbepoetin alfa</td>
<td>Protein</td>
<td>37100</td>
<td>µg/kg</td>
<td>2-CMT, linear</td>
<td>BW: 70.8 (36123)</td>
<td>CL = CL<xref ref-type="table-fn" rid="table-fn3-0091270010388648">*</xref> × (BW/70)<sup>0.623</sup> V = V × (BW/70)<sup>0.639</sup></td>
<td>140</td>
<td>0.623</td>
<td>6</td>
</tr>
<tr>
<td>Degarelix<sup><xref ref-type="table-fn" rid="table-fn6-0091270010388648">c</xref></sup></td>
<td>Peptide</td>
<td>1632</td>
<td>mg</td>
<td>3-CMT linear</td>
<td>No information</td>
<td>Body size is not a covariate</td>
<td>24</td>
<td>0</td>
<td>9</td>
</tr>
<tr>
<td>Emfilermin</td>
<td>Protein</td>
<td>22007</td>
<td>µg/kg</td>
<td>1-CMT linear</td>
<td>BW: 62 (48-83)</td>
<td>V = V<xref ref-type="table-fn" rid="table-fn3-0091270010388648">*</xref> + 6.7 × (WT − 62)</td>
<td>64</td>
<td>0</td>
<td>10</td>
</tr>
<tr>
<td>Enfuvirtide</td>
<td>Peptide</td>
<td>4492</td>
<td>mg</td>
<td>1-CMT, linear</td>
<td>BW: 72.2 (12.7)</td>
<td>CL/F = CL0<xref ref-type="table-fn" rid="table-fn3-0091270010388648">*</xref> + CL1<xref ref-type="table-fn" rid="table-fn3-0091270010388648">*</xref> × (BW/70)</td>
<td>534</td>
<td>0.5<sup><xref ref-type="table-fn" rid="table-fn4-0091270010388648">a</xref></sup></td>
<td>11</td>
</tr>
<tr>
<td>Erythropoietin alfa</td>
<td>Protein</td>
<td>30400</td>
<td>U/kg</td>
<td>1-CMT, linear</td>
<td>BW: 72.2 (18.96)</td>
<td>CL = CL<xref ref-type="table-fn" rid="table-fn3-0091270010388648">*</xref> × (BW/70)<sup>0.75</sup> V = V<xref ref-type="table-fn" rid="table-fn3-0091270010388648">*</xref> × (BW/70)<sup>1.37</sup></td>
<td>48</td>
<td>0.75</td>
<td>12</td>
</tr>
<tr>
<td>Erythropoietin beta</td>
<td>Protein</td>
<td>30000</td>
<td>µg/kg</td>
<td>1-CMT, linear</td>
<td>BW: 62.0 (51.0-79.0)</td>
<td>ka = ka<xref ref-type="table-fn" rid="table-fn3-0091270010388648">*</xref> × BW<sup>−1.92</sup> ke = ke<xref ref-type="table-fn" rid="table-fn3-0091270010388648">*</xref> V = V<xref ref-type="table-fn" rid="table-fn3-0091270010388648">*</xref> × (BW)<sup>0.776</sup></td>
<td>48</td>
<td>0.776<sup><xref ref-type="table-fn" rid="table-fn7-0091270010388648">d</xref></sup></td>
<td>13</td>
</tr>
<tr>
<td>Etanercept</td>
<td>Fusion protein</td>
<td>150000</td>
<td>mg</td>
<td>1-CMT, linear</td>
<td>BW: 73.6 (19.2)</td>
<td>CL/F = (CL/F)<xref ref-type="table-fn" rid="table-fn3-0091270010388648">*</xref> × (BW/70)<sup>0.75</sup> V/F = (V/F)<xref ref-type="table-fn" rid="table-fn3-0091270010388648">*</xref> × (BW/70)</td>
<td>182</td>
<td>0.75<sup><xref ref-type="table-fn" rid="table-fn8-0091270010388648">e</xref></sup></td>
<td>7</td>
</tr>
<tr>
<td>Hematide<sup><xref ref-type="table-fn" rid="table-fn6-0091270010388648">c</xref></sup></td>
<td>PEGylated peptide</td>
<td>76000</td>
<td>mg/kg</td>
<td>1-CMT, linear and nonlinear</td>
<td>BW: 76.9 (59-96)</td>
<td>BW is not a covariate</td>
<td>28</td>
<td>0</td>
<td>14</td>
</tr>
<tr>
<td>Lanreotide autogel</td>
<td>Peptide</td>
<td>1096</td>
<td>mg</td>
<td>3-CMT, linear</td>
<td>BW: 67.1 (12.4)</td>
<td>BW is not a covariate</td>
<td>50</td>
<td>0</td>
<td>15</td>
</tr>
<tr>
<td>Octreotide acetate</td>
<td>Peptide</td>
<td>1019</td>
<td>µg</td>
<td>1-CMT, linear</td>
<td>BW: 77.1 (51-103)</td>
<td>V = V<xref ref-type="table-fn" rid="table-fn3-0091270010388648">*</xref> × (BW/81)<sup>0.362</sup></td>
<td>59</td>
<td>0</td>
<td>16</td>
</tr>
<tr>
<td>Onercept</td>
<td>Fusion protein</td>
<td>18000</td>
<td>mg/kg</td>
<td>2-CMT, linear</td>
<td>BW: 73.1 (11.2)</td>
<td>BW is not a covariate</td>
<td>48</td>
<td>0</td>
<td>17</td>
</tr>
<tr>
<td>PEG-interferon alpha-2b</td>
<td>Protein</td>
<td>19271</td>
<td>µg/kg</td>
<td>1-CMT, linear</td>
<td>BW: 80 (41-149)</td>
<td>CL = CL<xref ref-type="table-fn" rid="table-fn3-0091270010388648">*</xref> × (BW/70)<sup>0.455</sup></td>
<td>817</td>
<td>0.455</td>
<td>18</td>
</tr>
<tr>
<td>Plitidepsin</td>
<td>Peptide</td>
<td>1110</td>
<td>mg/m<sup>2</sup></td>
<td>3-CMT, nonlinear</td>
<td>BSA: 1.78 (1.29-3.32)</td>
<td>BSA is not a covariate</td>
<td>283</td>
<td>0</td>
<td>19</td>
</tr>
<tr>
<td>Recombinant factor VIIa<sup><xref ref-type="table-fn" rid="table-fn6-0091270010388648">c</xref></sup></td>
<td>Protein</td>
<td>50000</td>
<td>µg/kg</td>
<td>2-CMT, linear</td>
<td>No information</td>
<td>BW is not a covariate</td>
<td>28</td>
<td>0</td>
<td>20</td>
</tr>
<tr>
<td>rhGH<sup><xref ref-type="table-fn" rid="table-fn6-0091270010388648">c</xref></sup></td>
<td>Protein</td>
<td>22000</td>
<td>mg/kg</td>
<td>1-CMT, nonlinear</td>
<td>BW: 77.9</td>
<td>BW is not a covariate</td>
<td>21</td>
<td>0</td>
<td>21</td>
</tr>
<tr>
<td>u-hFSH</td>
<td>Protein</td>
<td>30000</td>
<td>IU</td>
<td>1-CMT, linear</td>
<td>BW: 59 (7.4)</td>
<td>CL/F = (CL/F) × (1 + 0.017 × (BW − 58.5))</td>
<td>62</td>
<td>0.99<sup><xref ref-type="table-fn" rid="table-fn5-0091270010388648">b</xref></sup></td>
<td>22</td>
</tr>
</tbody>
</table>
<table-wrap-foot>
<fn id="table-fn2-0091270010388648">
<p>BSA, body surface area; BW, body weight; rhGH, recombinant human growth hormone; u-hFSH, urinary human follicle-stimulating hormone.</p>
</fn>
<fn id="table-fn3-0091270010388648">
<label>*</label>
<p>Parameter value without body size correction.</p>
</fn>
<fn id="table-fn4-0091270010388648">
<label>a.</label>
<p>The α value was obtained as follows: first, a series of CL values over the range of reported body size were generated based on the reported original covariate model; then, the generated CL versus body size data were fitted using <xref ref-type="disp-formula" rid="disp-formula1-0091270010388648">equation (1)</xref> to obtain the α value.</p>
</fn>
<fn id="table-fn5-0091270010388648">
<label>b.</label>
<p>z = 1.93 for participants with a bacterial infection and 1 for noninfected participants.<sup><xref ref-type="bibr" rid="bibr8-0091270010388648">8</xref></sup></p>
</fn>
<fn id="table-fn6-0091270010388648">
<label>c.</label>
<p>Biologics whose population pharmacokinetic models were developed based on data from fewer than 30 patients.</p>
</fn>
<fn id="table-fn7-0091270010388648">
<label>d.</label>
<p>The α value was derived using equation ke = CL/V.</p>
</fn>
<fn id="table-fn8-0091270010388648">
<label>e.</label>
<p>The α value was obtained by trying different values for α during the modeling and found that a value of 0.75 best described the data.</p>
</fn>
</table-wrap-foot>
</table-wrap>
<p>Mixed-effect models were used to describe the PK and/or PD of all the selected therapeutic peptides and proteins. The <italic>j</italic>th observation for the <italic>i</italic>th individual was given by</p>
<p><disp-formula id="disp-formula2-0091270010388648">
<label>(2)</label>
<mml:math display="block" id="math3-0091270010388648">
<mml:mrow>
<mml:msub>
<mml:mi>y</mml:mi>
<mml:mrow>
<mml:mi>i</mml:mi>
<mml:mi>j</mml:mi>
</mml:mrow>
</mml:msub>
<mml:mo>=</mml:mo>
<mml:mi>f</mml:mi>
<mml:mo stretchy="false">(</mml:mo>
<mml:msub>
<mml:mi>θ</mml:mi>
<mml:mi>i</mml:mi>
</mml:msub>
<mml:mo>,</mml:mo>
<mml:msub>
<mml:mi>t</mml:mi>
<mml:mrow>
<mml:mi>i</mml:mi>
<mml:mi>j</mml:mi>
</mml:mrow>
</mml:msub>
<mml:mo stretchy="false">)</mml:mo>
<mml:mo stretchy="false">(</mml:mo>
<mml:mn>1</mml:mn>
<mml:mo>+</mml:mo>
<mml:msub>
<mml:mi>ε</mml:mi>
<mml:mrow>
<mml:mn>1</mml:mn>
<mml:mi>i</mml:mi>
<mml:mi>j</mml:mi>
</mml:mrow>
</mml:msub>
<mml:mo stretchy="false">)</mml:mo>
<mml:mo>+</mml:mo>
<mml:msub>
<mml:mi>ε</mml:mi>
<mml:mrow>
<mml:mn>2</mml:mn>
<mml:mi>i</mml:mi>
<mml:mi>j</mml:mi>
</mml:mrow>
</mml:msub>
</mml:mrow>
</mml:math>
<graphic alternate-form-of="disp-formula2-0091270010388648" xlink:href="10.1177_0091270010388648-eq2.tif"/>
</disp-formula></p>
<p>where θ<sub><italic>i</italic></sub> is a set of PK and/or PD parameters for the <italic>i</italic>th individual, and ϵ<sub>1<italic>ij</italic></sub> and ϵ<sub>2<italic>ij</italic></sub> are the residual errors following normal distributions with a mean of zero and variance of <inline-formula id="inline-formula2-0091270010388648">
<mml:math display="inline" id="math4-0091270010388648">
<mml:mrow>
<mml:msubsup>
<mml:mi>σ</mml:mi>
<mml:mn>1</mml:mn>
<mml:mn>2</mml:mn>
</mml:msubsup>
</mml:mrow>
</mml:math>
</inline-formula> and <inline-formula id="inline-formula3-0091270010388648">
<mml:math display="inline" id="math5-0091270010388648">
<mml:mrow>
<mml:msubsup>
<mml:mi>σ</mml:mi>
<mml:mn>2</mml:mn>
<mml:mn>2</mml:mn>
</mml:msubsup>
</mml:mrow>
</mml:math>
</inline-formula>, respectively. θ<sub><italic>i</italic></sub> can be further described by</p>
<p><disp-formula id="disp-formula3-0091270010388648">
<label>(3)</label>
<mml:math display="block" id="math6-0091270010388648">
<mml:mrow>
<mml:msub>
<mml:mi>θ</mml:mi>
<mml:mi>i</mml:mi>
</mml:msub>
<mml:mo>=</mml:mo>
<mml:mi>g</mml:mi>
<mml:mo stretchy="false">(</mml:mo>
<mml:msub>
<mml:mi>z</mml:mi>
<mml:mi>i</mml:mi>
</mml:msub>
<mml:mo>,</mml:mo>
<mml:mi>θ</mml:mi>
<mml:mo stretchy="false">)</mml:mo>
<mml:mo>+</mml:mo>
<mml:msub>
<mml:mi>η</mml:mi>
<mml:mi>i</mml:mi>
</mml:msub>
</mml:mrow>
</mml:math>
<graphic alternate-form-of="disp-formula3-0091270010388648" xlink:href="10.1177_0091270010388648-eq3.tif"/>
</disp-formula></p>
<p>where <italic>z</italic><sub>i</sub> is a set of fixed effects on the PK or PD parameters, θ is a set of typical population values of PK and/or PD parameters, and η<sub><italic>i</italic></sub> is the intersubject variability following a normal distribution with a mean of zero and variance of Ω<sup>2</sup>. Simulation analysis was conducted using NONMEM (version VI; GloboMax, Hanover, Maryland).</p>
</sec>
<sec id="section4-0091270010388648">
<title>PK and/or PD Simulation</title>
<sec id="section5-0091270010388648">
<title>Population performance</title>
<p>Simulations to evaluate population performance of a dosing approach were conducted in the same way as previously described.<sup><xref ref-type="bibr" rid="bibr1-0091270010388648">1</xref></sup> Briefly, Monte Carlo simulation was conducted using the final PK and/or PD model reported for each peptide or protein to obtain the concentration-time profiles following both fixed dosing and body size–based dosing approaches. The dose used for simulation was the dose recommended in the labeling for marketed products or the dose used in the reported clinical trials for biologics under development. The median value of body size (BW or BSA) was used as the conversion factor for dose determination so that the dose used in the fixed-dosing approach is the same as the dose for the participants with median (typical) body size in the body size–based dosing approach. For all simulation studies, 1000 participants were simulated per dosing approach. The sampling points were chosen based on the PK or PD properties of therapeutic peptides and proteins, and the same sampling schedule was used for both dosing approaches.</p>
<p>For each simulation study, with the exception of BW, values of influential covariates were randomly generated using S-PLUS 7.0 (TIBCO, Palo Alto, California) assuming normal or lognormal distribution. The values of parameters used for generating these covariates were selected by trial and error, with a goal of reproducing the patient population by matching the median, standard deviation, or the range of covariates to those reported in the corresponding population PK/PD study. BSA was generated assuming normal distribution with a median of 1.82 m<sup>2</sup> and a range of 1.2 to 2.4 m<sup>2</sup>.<sup><xref ref-type="bibr" rid="bibr1-0091270010388648">1</xref></sup></p>
<p>BW values were generated as previously described.<sup><xref ref-type="bibr" rid="bibr1-0091270010388648">1</xref></sup> Historical data have shown that BW does not follow normal distribution, whereas transformation of BW by a power function Z = BW<sup>−0.5</sup> was shown to give a better approximation to normal distribution and can adequately describe the right tail of natural BW distribution.<sup><xref ref-type="bibr" rid="bibr4-0091270010388648">4</xref></sup> Therefore, the BW values were generated assuming a normal distribution of Z (Z = BW<sup>−0.5</sup>). The randomly generated BW (1000 participants) has a median of 75.7 kg and a range of 38.8 to 187.2 kg, which in general covers the range of those reported in the population PK/PD studies for selected peptides and proteins (<xref ref-type="table" rid="table2-0091270010388648">Table II</xref>).</p>
</sec>
<sec id="section6-0091270010388648">
<title>Individual performance</title>
<p>To evaluate the individual performance, we simulated the PK profiles for the participants with typical, low extreme, and high extreme body size. The typical, low extreme, and high extreme BW/BSA used in this study were 75.7 kg/1.8 m<sup>2</sup>, 40 kg/1.3 m<sup>2</sup>, and 140 kg/2.3 m<sup>2</sup>, respectively. For covariates other than BW/BSA, typical values were used. The intersubject variability and residual errors were all set to zero for the simulations conducted for both dosing approaches.</p>
</sec>
</sec>
<sec id="section7-0091270010388648">
<title>Calculation of α Values</title>
<p>A simple way to assess whether fixed dosing or body size–based dosing may be better in reducing intersubject variability in AUC is to look at the α value of the body size effect on CL, as defined in <xref ref-type="disp-formula" rid="disp-formula1-0091270010388648">equation (1)</xref>, obtained from covariate analysis. However, the covariate models used to characterize the effect of body size on CL for the selected molecules are not all in the form of <xref ref-type="disp-formula" rid="disp-formula1-0091270010388648">equation (1)</xref> (<xref ref-type="table" rid="table2-0091270010388648">Table II</xref>). Therefore, an effort was made to obtain the α values for all biologics evaluated. For those whose α values were not reported, the following steps were used to obtain the α value for each molecule: (1) generate a series of CL values over the range of body size reported based on the reported original covariate model and (2) fit the generated CL versus body size data using <xref ref-type="disp-formula" rid="disp-formula1-0091270010388648">equation (1)</xref> to obtain the α value using WinNonlin 5.2 (Pharsight, Mountain View, California).</p>
<sec id="section8-0091270010388648">
<title>AUC calculation</title>
<p>The AUC for each participant was calculated as dose/CL if the molecule exhibited a linear PK. When the molecule exhibited a nonlinear PK, the AUC was calculated by integration of the concentration-time curve by the trapezoidal method using S-PLUS.</p>
</sec>
<sec id="section9-0091270010388648">
<title>PK C<sub>max</sub> (PD C<sub>max</sub> or C<sub>min</sub>) determination</title>
<p>The maximum concentration (C<sub>max</sub>) for each participant was determined as the maximal concentration from the simulated concentration-time profile of the participant. For PD measurements, C<sub>max</sub> or the minimum concentration (C<sub>min</sub>) of the PD marker, whichever reflects the maximal drug effect, was determined from the PD marker-time profile of the participant.</p>
</sec>
</sec>
<sec id="section10-0091270010388648">
<title>Performance Evaluation</title>
<p>The performance of a dosing approach in terms of reducing intersubject variability in AUC was assessed by evaluating the α value of the CL versus body size relationship as described by <xref ref-type="disp-formula" rid="disp-formula1-0091270010388648">equation (1)</xref> based on the following criteria:</p>
<list id="list1-0091270010388648" list-type="simple">
<list-item><p>α &lt; 0.5—fixed dose is better.</p></list-item>
<list-item><p>α = 0.5—fixed and body size–based dosing are similar.</p></list-item>
<list-item><p>α &gt; 0.5—body size–based dosing is better.</p></list-item>
</list>
<p>These criteria apply to both population and individual performances. To be consistent with the mAb paper<sup><xref ref-type="bibr" rid="bibr1-0091270010388648">1</xref></sup> and to confirm the predictive performance of the α value, results from simulation studies for the comparison of the 2 dosing approaches were also presented as described below.</p>
<p>Population performance was assessed by comparing the intersubject variability (expressed as % coefficient of variation [CV%]) in the exposure (AUC and C<sub>max</sub>) of 1000 participants simulated following the 2 dosing approaches. The dosing approach that produced less intersubject variability provides a better population performance.</p>
<p>Individual performance was evaluated by comparing the percentage difference in the exposure between participants with extreme body size and typical body size following the 2 dosing approaches. The dosing approach that resulted in a smaller difference in PK or PD exposure between participants with extreme body size and those with typical body size has a better individual performance.</p>
</sec>
<sec id="section11-0091270010388648">
<title>Contribution of Body Size Effect to Overall Intersubject Variability of Relevant PK Parameters</title>
<p>A simulated PK data set of 100 participants was generated using the published “final” PK models, including all influential covariates following a fixed dose. The relevant covariate values were randomly generated as described above. This simulated data set was then fitted using both the “final” model and the “reduced” model, which excluded body size as covariate(s) for any PK parameters. The percentage change in the intersubject variability of relevant PK parameters by the “final” model in comparison to the “reduced” model was calculated to determine the contribution of body size effect to the overall intersubject variability of the relevant PK parameters.</p>
</sec>
</sec>
<sec id="section12-0091270010388648" sec-type="results|discussion">
<title>Results and Discussion</title>
<sec id="section13-0091270010388648">
<title>Data Collection</title>
<p>A total of 18 therapeutic biologics were identified based on the data collection criteria specified in the Methods section (<xref ref-type="table" rid="table1-0091270010388648">Tables I</xref> and <xref ref-type="table" rid="table2-0091270010388648">II</xref>), including 7 therapeutic peptides and 11 therapeutic proteins. The effect of body size on various PK parameters, including CL, intercompartment clearance (Q), volume of the central compartment (V or V1), and volume of the peripheral compartment (V2), is summarized in <xref ref-type="table" rid="table2-0091270010388648">Table II</xref>. Body size has been found to be covariate(s) of 1 or more of the PK parameters for 11 therapeutic biologics (<xref ref-type="table" rid="table2-0091270010388648">Table II</xref>). The effect of body size on PK parameters of these 11 biologics was generally well estimated with a couple of exceptions. The relative standard error (RSE) or 95% confidence intervals of the parameters that describe the body size effect on CL and/or volume of distribution (V/V1 or V2) are summarized below to help the interpretation of these simulation studies. The RSE ranged from 16% to 26% for CL and 12% to 33% for volumes of distribution except for octreotide (89.5% for V). In the case of darbepoetin alfa, where standard error of the estimate was not reported, 95% confidence intervals were (0.172, 1.07) for CL and (−0.01, 1.29) for V.</p>
<p>It should also be pointed out that for 4 of the selected biologics—namely, degarelix, hematide, recombinant factor VIIa, and rhGH—although body size had been found not to be covariates of their PK parameters, the population PK models were developed based on data from fewer than 30 patients (<xref ref-type="table" rid="table2-0091270010388648">Table II</xref>). Therefore, some caution needs to be exercised in interpretation of the following results.</p>
<p>Among these 18 selected biologics, 12 are administered based on their body size in adult patients (<xref ref-type="table" rid="table1-0091270010388648">Table I</xref>). Interestingly, for some products that are administered using body size–based dosing, such as hematide and onercept (<xref ref-type="table" rid="table1-0091270010388648">Table I</xref>), body size measures (BW) had been shown not to be a covariate of their PK parameters (<xref ref-type="table" rid="table2-0091270010388648">Table II</xref>).</p>
</sec>
<sec id="section14-0091270010388648">
<title>Dosing Approach Performance</title>
<sec id="section15-0091270010388648">
<title>Performance Evaluation Based on AUC</title>
<p>As discussed in the mAbs work,<sup><xref ref-type="bibr" rid="bibr1-0091270010388648">1</xref></sup> the comparative performance of the 2 dosing approaches based on AUC can be simply assessed by the α values, the exponent of the power function as defined in <xref ref-type="disp-formula" rid="disp-formula1-0091270010388648">equation (1)</xref>, with α value of 0.5 as the separation point. As such, the α values that describe the body size effect on CL were obtained for all the 18 selected therapeutic biologics and listed in <xref ref-type="table" rid="table2-0091270010388648">Table II</xref>. These α values were either directly obtained from the published reports or obtained in such a way as described in the Methods section. For products with body size found not to be a covariate of CL, a zero value was assigned to α. As shown in <xref ref-type="table" rid="table2-0091270010388648">Table II</xref>, 12 of 18 molecules had α values less than 0.5, 1 molecule had an α value equal to 0.5, and 5 molecules had α values greater than 0.5. These results suggested that fixed dosing would perform better for 12 molecules (α &lt; 0.5), body size–based dosing would perform better for 5 molecules (α &gt; 0.5), and the 2 dosing approaches would perform similarly for 1 molecule (α = 0.5).</p>
<p>The results of the simulation studies for comparing the performance of these 2 dosing approaches at the population level are presented in <xref ref-type="fig" rid="fig2-0091270010388648">Figure 2A</xref>. Consistent with the prediction based on the α values, 5 therapeutic biologics with α &gt; 0.5 exhibited less intersubject variability in AUC when body size–based dosing was adopted, whereas the other 12 biologics with α &lt; 0.5 exhibited less variability in AUC when fixed dosing was used. For the molecule with α = 0.5 (enfuvirtide), the variability was similar for the 2 dosing approaches. Similar results were also obtained for individual performance (<xref ref-type="fig" rid="fig3-0091270010388648">Figure 3A</xref>). For all therapeutic biologics investigated, the dosing approach that had better population performance also had better individual performance. It should be noted that the zero difference in AUC between patients with extreme body size and typical body size following a fixed dose for daptomycin, degarelix, emfilermin, lanreotide autogel, octreotide acetate, onercept, recombinant factor VIIa, and rhGH is a result of the lack of BW effect on their CL (<xref ref-type="fig" rid="fig3-0091270010388648">Figure 3A</xref>).</p>
<fig id="fig2-0091270010388648" position="float">
<label>Figure 2.</label>
<caption><p>Comparison of the intersubject variability of simulated (A) AUC and (B) C<sub>max</sub> of 1000 participants after receiving a single fixed (solid bar) dose or a body size (BW/BSA)–based dose (open bar). rhGH, recombinant human growth hormone; u-hFSH, urinary human follicle-stimulating hormone.</p></caption>
<graphic xlink:href="10.1177_0091270010388648-fig2.tif"/>
</fig>
<fig id="fig3-0091270010388648" position="float">
<label>Figure 3.</label>
<caption><p>Comparison of the deviation (% difference) of (A) AUC and (B) C<sub>max</sub> for participants with low (open bar) and high (solid bar) extreme body size (body weight [BW]/body surface area [BSA]) measurements from the typical values (AUC and C<sub>max</sub> for participants with median body size measurements) after a fixed dose (red) or a body size (BW/BSA)–based dose (black). rhGH, recombinant human growth hormone; u-hFSH, urinary human follicle-stimulating hormone.</p></caption>
<graphic xlink:href="10.1177_0091270010388648-fig3.tif"/>
</fig>
<p>The consistent conclusions obtained based on the α values and from the simulation studies further reconciled the recommendation of using the α value to select the optimal dosing approach if AUC is the exposure parameter of the main concern. This approach can also be used for comparative performance evaluation based on C<sub>max</sub> if body size is only a covariate for the V/V1 but not for any other parameters, as is the case for emfilermin and octreotide. However, if the body size variable is a covariate on more than one PK parameter that could affect C<sub>max</sub>, simulation needs to be conducted to evaluate the performance of the 2 dosing approaches in terms of reducing C<sub>max</sub> variability.</p>
</sec>
<sec id="section16-0091270010388648">
<title>Performance Evaluation Based on C<sub>max</sub></title>
<p>The population and individual performances of the 2 dosing approaches based on C<sub>max</sub> were evaluated by simulation studies and shown in <xref ref-type="fig" rid="fig2-0091270010388648">Figures 2B</xref> and <xref ref-type="fig" rid="fig3-0091270010388648">3B</xref>, respectively. At the population level, body size–based dosing resulted in less intersubject variability in C<sub>max</sub> for 7 of 18 biologics, whereas fixed dosing produced less variability in C<sub>max</sub> for the other 11 biologics (<xref ref-type="fig" rid="fig2-0091270010388648">Figure 2B</xref>). At the individual level, body size–based dosing produced a smaller percentage difference in C<sub>max</sub> between participants with extreme and typical body sizes for 6 of 18 biologics, whereas fixed dosing produced a smaller percentage difference for the other 12 biologics (<xref ref-type="fig" rid="fig3-0091270010388648">Figure 3B</xref>). The results from both population- and individual-level evaluations are again very consistent with the only exception of enfuvirtide, for which body size–based dosing was shown to have better individual performance but worse population performance.</p>
<p>It was noted that body size–based dosing tends to overdose patients with large body size and underdose patients with small body size. The opposite is true for fixed dosing, that is, overdose patients with small body size but underdose patients with large body size (<xref ref-type="fig" rid="fig3-0091270010388648">Figure 3A</xref>,<xref ref-type="fig" rid="fig3-0091270010388648">B</xref>).</p>
</sec>
<sec id="section17-0091270010388648">
<title>Performance Evaluation Based on PD</title>
<p>Among the 18 selected biologics, PD models, in addition to the PK models, have been reported for 3 products (abatacept, darbepoetin alfa, and etanercept).<sup><xref ref-type="bibr" rid="bibr5-0091270010388648">5</xref>-<xref ref-type="bibr" rid="bibr7-0091270010388648">7</xref></sup> Therefore, the 2 dosing approaches were also evaluated for their performance in reducing PD variability. The PD response of abatacept—namely, IL-6 levels—was described by an indirect response model, in which the IL-6 degradation rate was stimulated by abatacept according to an E<sub>max</sub> model.<sup><xref ref-type="bibr" rid="bibr5-0091270010388648">5</xref></sup> The PD response of darbepoetin—namely, the hemoglobin levels—was described by a modified indirect response model, wherein serum darbepoetin stimulated the production of hemoglobin through an E<sub>max</sub> model after weekly administration of darbepoetin.<sup><xref ref-type="bibr" rid="bibr6-0091270010388648">6</xref></sup> A logistic regression model was adopted to describe the exposure-response relationship for etanercept.<sup><xref ref-type="bibr" rid="bibr7-0091270010388648">7</xref></sup> The cumulative AUC of etanercept was used as the exposure variable, and the American College of Rheumatology response criterion of 20% improvement (ACR20) was used as the binominal clinical outcome. Body size measures were not identified as covariates for any PD parameters in any of these PD models. The results of PD performance for all 3 biologics are shown in <xref ref-type="fig" rid="fig4-0091270010388648">Figure 4</xref>. Although the comparative performance of 2 dosing approaches in reducing PD variability is in the same order as that in reducing drug exposure variability, the difference between the performance of the 2 dosing approaches based on PD is smaller than that based on the PK for all these 3 therapeutic agents (<xref ref-type="fig" rid="fig2-0091270010388648">Figures 2</xref>-<xref ref-type="fig" rid="fig4-0091270010388648">4</xref>). For example, the intersubject variability in drug exposure of etanercept following the 2 dosing approaches was shown to be 47.5% (fixed dosing) versus 45.7% (body sized–based dosing) for AUC and 37.4% (fixed dosing) versus 31.4% (body size–based dosing) for C<sub>max</sub> at the population level. However, the intersubject variability in its PD measures was 82.2% (fixed dosing) versus 81.9% (body size–based dosing) for AUC and 70.8% (fixed dosing) versus 70.3% (body size–based dosing) for C<sub>max</sub> of the PD effect.</p>
<fig id="fig4-0091270010388648" position="float">
<label>Figure 4.</label>
<caption><p>(A) The intersubject variability of AUC and C<sub>max</sub> (or C<sub>min</sub>) of the pharmacodynamic (PD) markers for abatacept, darbepoetin alfa, and etanercept across 1000 participants after fixed (solid bar) and body size–based (open bar) dosing. (B) Deviation of AUC and C<sub>max</sub> (or C<sub>min</sub>) of the PD markers for participants with low (open bar) and high (solid bar) extreme body weight (BW) from the typical values after a fixed (red) and a body size–based (black) dose of abatacept, darbepoetin alfa, and etanercept. The AUC and C<sub>max</sub> (or C<sub>min</sub>) of the PD markers are defined as follows: for abatacept, AUC represents the area between the IL-6 baseline and serum IL-6 concentration-time curve, and C<sub>min</sub> represents the minimal concentration of serum IL-6; for darbepoetin, AUC represents the area between the hemoglobin concentration-time curve and hemoglobin baseline, and C<sub>max</sub> represents the maximal concentration of hemoglobin; for etanercept, AUC represents the area under the probability of achieving an American College of Rheumatology response criterion of 20% improvement (ACR20) response-time curve, and C<sub>max</sub> represents the maximal probability of achieving an ACR20 response.</p></caption>
<graphic xlink:href="10.1177_0091270010388648-fig4.tif"/>
</fig>
<p>As the ultimate goal of a clinical trial is to achieve its efficacy and safety endpoints, efficacy data, safety data, and data of surrogate PD markers, when available, are more important than PK data alone. The smaller difference in intersubject PD variability between the 2 dosing approaches suggested that the clinical benefit, if any, of body size–based dosing could be further “diluted” in terms of drug response or PD measurements, as shown in this study for abatacept, darbepoetin alfa, and etanercept.</p>
</sec>
</sec>
<sec id="section18-0091270010388648">
<title>Contribution of Body Size Effect to Overall Intersubject Variability in PK Parameters</title>
<p>The contribution of the effect of body size to the overall intersubject variability of relevant PK parameters was evaluated for 8 therapeutic biologics, and the results are summarized in <xref ref-type="table" rid="table3-0091270010388648">Table III</xref>. It was observed that the effect of body size had a small and, in some cases, moderate contribution to the overall intersubject variability of major PK parameters, ranging from 1.8% to 18.4% for CL and from 0.42% to 26.9% for V/V1 (<xref ref-type="table" rid="table3-0091270010388648">Table III</xref>). Interestingly, the α values for the body size effect on relevant PK parameters appear to correlate with the relative contribution of body size to the overall variability, although the rank orders of the two are not exactly the same. This discrepancy may be due to the difference in the extent of the contribution of other identified and unidentified factors, such as demographic characteristics and disease conditions.</p>
<table-wrap id="table3-0091270010388648" position="float">
<label>Table III</label>
<caption><p>Percentage Contribution of Body Size Measurements to the Overall Intersubject Variability of Pharmacokinetic Parameters</p></caption>
<graphic alternate-form-of="table3-0091270010388648" xlink:href="10.1177_0091270010388648-table3.tif"/>
<table>
<colgroup>
<col align="left"/>
<col align="char" char="."/>
<col align="char" char="."/>
<col align="char" char="."/>
<col align="char" char="."/>
</colgroup>
<thead>
<tr>
<th/>
<th align="center" colspan="2">% Contribution of BW to the Intersubject Variability</th>
<th align="center" colspan="2">α Value</th>
</tr>
<tr>
<th align="left">Biologics</th>
<th align="center">CL</th>
<th align="center">V/V1</th>
<th align="center">CL</th>
<th align="center">V/V1</th>
</tr>
</thead>
<tbody>
<tr>
<td>u-hFSH</td>
<td>13.6</td>
<td align="center">NA</td>
<td>0.99</td>
<td>0</td>
</tr>
<tr>
<td>Etanercept</td>
<td>18.4</td>
<td>26.9</td>
<td>0.75</td>
<td>1</td>
</tr>
<tr>
<td>Erythropoietin alfa</td>
<td>8.48</td>
<td>11</td>
<td>0.75</td>
<td>1.37</td>
</tr>
<tr>
<td>Darbepoetin alfa</td>
<td>1.80</td>
<td>0.42</td>
<td>0.623</td>
<td>0.639</td>
</tr>
<tr>
<td>Enfuvirtide</td>
<td>3.17</td>
<td align="center">NA</td>
<td>0.5</td>
<td>0</td>
</tr>
<tr>
<td>PEG-interferon alpha-2b</td>
<td>2.12</td>
<td align="center">NA</td>
<td>0.455</td>
<td>0</td>
</tr>
<tr>
<td>Abatacept</td>
<td>3.46</td>
<td align="center">NA</td>
<td>0.4</td>
<td>0</td>
</tr>
<tr>
<td>Emfilermin</td>
<td align="center">NA</td>
<td>4.16</td>
<td>0</td>
<td>1.66</td>
</tr>
</tbody>
</table>
<table-wrap-foot>
<fn id="table-fn9-0091270010388648">
<p>BW, body weight; NA, not applicable; u-hFSH, urinary human follicle-stimulating hormone.</p>
</fn>
</table-wrap-foot>
</table-wrap>
<p>When body size only explains a very small percentage of the intersubject variability—for example, in the case of darbepoetin alfa and PEG-interferon alpha-2b—adjusting the dose based on body size would lead to a minimal reduction in the variability in AUC. On the other hand, if body size is a major source for intersubject variability, body size–based dosing may provide a clinical benefit when supported by other factors, such as a narrow therapeutic window.</p>
</sec>
<sec id="section19-0091270010388648">
<title>Relationship Between the Type of Therapeutic Biologics and Body Size Effect on PK</title>
<p>The therapeutic biologics investigated for this analysis included 7 therapeutic peptides and 11 therapeutic proteins. Among the 11 therapeutic proteins, including 3 fusion proteins and 1 pegylated protein, no apparent correlation between either the type or the size of therapeutic proteins and the body size effect on their PK was observed. However, it was noted that the α values of body size effect on CL for the 7 peptides were all less than 0.5, with 6 having α values equal to 0. As a result, fixed dosing would work better for all the peptides evaluated. Whether this can be generalized to other peptides remains a topic for further investigation when more data become available.</p>
</sec>
</sec>
<sec id="section20-0091270010388648" sec-type="conclusions">
<title>Conclusion</title>
<p>As a continuation of the mAb work,<sup><xref ref-type="bibr" rid="bibr1-0091270010388648">1</xref></sup> body size–based dosing and fixed dosing were evaluated for 18 non-mAb therapeutic biologics in terms of their population and individual performances in reducing intersubject PK and/or PD variability in adult patients. The results demonstrated that body size–based dosing did not always result in less intersubject variability in drug exposure and PD measurements. In fact, fixed dosing showed better performance for 12 of 18 evaluated biologics based on both AUC and C<sub>max</sub> assessments. Even if the 4 biologics whose population PK models were developed based on data from fewer than 30 patients were excluded from the analysis, fixed dosing would still show better performance for 8 of 14 evaluated biologics. Therefore, the recommendations made for mAbs dosing<sup><xref ref-type="bibr" rid="bibr1-0091270010388648">1</xref></sup> also apply to non-mAb biologics. For adult FIH studies, fixed dosing is recommended because it offers advantages in ease of dosing preparation, reduced cost, and reduced chance of dosing errors. When sufficient data become available, a full assessment of body size effect on PK and/or PD should be conducted. The final dosing approach for phase 3 trials in adults should be selected based on the established body size effect on the PK and PD, the therapeutic window of the therapeutic products, and other factors that may affect the outcome of the study.</p>
</sec>
</body>
<back>
<fn-group>
<fn fn-type="financial-disclosure">
<p>Financial disclosure: None declared.</p>
</fn>
</fn-group>
<ref-list>
<title>References</title>
<ref id="bibr1-0091270010388648">
<label>1.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Wang</surname><given-names>DD</given-names></name>
<name><surname>Zhang</surname><given-names>S</given-names></name>
<name><surname>Zhao</surname><given-names>H</given-names></name>
<name><surname>Men</surname><given-names>AY</given-names></name>
<name><surname>Parivar</surname><given-names>K</given-names></name>
</person-group>. <article-title>Fixed dosing versus body size-based dosing of monoclonal antibodies in adult clinical trials</article-title>. <source>J Clin Pharmacol</source>. <year>2009</year>;<volume>49</volume>:<fpage>1012</fpage>-<lpage>1024</lpage>.</citation>
</ref>
<ref id="bibr2-0091270010388648">
<label>2.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Lin</surname><given-names>JH</given-names></name>
</person-group>. <article-title>Pharmacokinetics of biotech drugs: peptides, proteins and monoclonal antibodies</article-title>. <source>Curr Drug Metab</source>. <year>2009</year> <month>Jun</month> <day>1</day>. [<comment>Epub ahead of print</comment>]</citation>
</ref>
<ref id="bibr3-0091270010388648">
<label>3.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Wang</surname><given-names>W</given-names></name>
<name><surname>Wang</surname><given-names>EQ</given-names></name>
<name><surname>Balthasar</surname><given-names>JP</given-names></name>
</person-group>. <article-title>Monoclonal antibody pharmacokinetics and pharmacodynamics</article-title>. <source>Clin Pharmacol Ther</source>. <year>2008</year>;<volume>84</volume>:<fpage>548</fpage>-<lpage>558</lpage>.</citation>
</ref>
<ref id="bibr4-0091270010388648">
<label>4.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Hermanussen</surname><given-names>M</given-names></name>
<name><surname>Danker-Hopfe</surname><given-names>H</given-names></name>
<name><surname>Weber</surname><given-names>GW</given-names></name>
</person-group>. <article-title>Body weight and the shape of the natural distribution of weight, in very large samples of German, Austrian and Norwegian conscripts</article-title>. <source>Int J Obes Relat Metab Disord</source>. <year>2001</year>;<volume>25</volume>:<fpage>1550</fpage>-<lpage>1553</lpage>.</citation>
</ref>
<ref id="bibr5-0091270010388648">
<label>5.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Roy</surname><given-names>A</given-names></name>
<name><surname>Mould</surname><given-names>DR</given-names></name>
<name><surname>Wang</surname><given-names>XF</given-names></name>
<name><surname>Tay</surname><given-names>L</given-names></name>
<name><surname>Raymond</surname><given-names>R</given-names></name>
<name><surname>Pfister</surname><given-names>M</given-names></name>
</person-group>. <article-title>Modeling and simulation of abatacept exposure and interleukin-6 response in support of recommended doses for rheumatoid arthritis</article-title>. <source>J Clin Pharmacol</source>. <year>2007</year>;<volume>47</volume>:<fpage>1408</fpage>-<lpage>1420</lpage>.</citation>
</ref>
<ref id="bibr6-0091270010388648">
<label>6.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Agoram</surname><given-names>B</given-names></name>
<name><surname>Heatherington</surname><given-names>AC</given-names></name>
<name><surname>Gastonguay</surname><given-names>MR</given-names></name>
</person-group>. <article-title>Development and evaluation of a population pharmacokinetic-pharmacodynamic model of darbepoetin alfa in patients with nonmyeloid malignancies undergoing multicycle chemotherapy</article-title>. <source>AAPS J</source>. <year>2006</year>;<volume>8</volume>:<fpage>E552</fpage>-<lpage>E563</lpage>.</citation>
</ref>
<ref id="bibr7-0091270010388648">
<label>7.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Lee</surname><given-names>H</given-names></name>
<name><surname>Kimko</surname><given-names>HC</given-names></name>
<name><surname>Rogge</surname><given-names>M</given-names></name>
<name><surname>Wang</surname><given-names>D</given-names></name>
<name><surname>Nestorov</surname><given-names>I</given-names></name>
<name><surname>Peck</surname><given-names>CC</given-names></name>
</person-group>. <article-title>Population pharmacokinetic and pharmacodynamic modeling of etanercept using logistic regression analysis</article-title>. <source>Clin Pharmacol Ther</source>. <year>2003</year>;<volume>73</volume>:<fpage>348</fpage>-<lpage>365</lpage>.</citation>
</ref>
<ref id="bibr8-0091270010388648">
<label>8.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Dvorchik</surname><given-names>B</given-names></name>
<name><surname>Arbeit</surname><given-names>RD</given-names></name>
<name><surname>Chung</surname><given-names>J</given-names></name>
<name><surname>Liu</surname><given-names>S</given-names></name>
<name><surname>Knebel</surname><given-names>W</given-names></name>
<name><surname>Kastrissios</surname><given-names>H</given-names></name>
</person-group>. <article-title>Population pharmacokinetics of daptomycin</article-title>. <source>Antimicrob Agents Chemother</source>. <year>2004</year>;<volume>48</volume>:<fpage>2799</fpage>-<lpage>2807</lpage>.</citation>
</ref>
<ref id="bibr9-0091270010388648">
<label>9.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Tornoe</surname><given-names>CW</given-names></name>
<name><surname>Agerso</surname><given-names>H</given-names></name>
<name><surname>Nielsen</surname><given-names>HA</given-names></name>
<name><surname>Madsen</surname><given-names>H</given-names></name>
<name><surname>Jonsson</surname><given-names>EN</given-names></name>
</person-group>. <article-title>Pharmacokinetic/pharmacodynamic modelling of GnRH antagonist degarelix: a comparison of the non-linear mixed-effects programs NONMEM and NLME</article-title>. <source>J Pharmacokinet Pharmacodyn</source>. <year>2004</year>;<volume>31</volume>:<fpage>441</fpage>-<lpage>461</lpage>.</citation>
</ref>
<ref id="bibr10-0091270010388648">
<label>10.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Goggin</surname><given-names>T</given-names></name>
<name><surname>Nguyen</surname><given-names>QT</given-names></name>
<name><surname>Munafo</surname><given-names>A</given-names></name>
</person-group>. <article-title>Population pharmacokinetic modelling of Emfilermin (recombinant human leukaemia inhibitory factor, r-hLIF) in healthy postmenopausal women and in infertile patients undergoing in vitro fertilization and embryo transfer</article-title>. <source>Br J Clin Pharmacol</source>. <year>2004</year>;<volume>57</volume>:<fpage>576</fpage>-<lpage>585</lpage>.</citation>
</ref>
<ref id="bibr11-0091270010388648">
<label>11.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Mould</surname><given-names>DR</given-names></name>
<name><surname>Zhang</surname><given-names>X</given-names></name>
<name><surname>Nieforth</surname><given-names>K</given-names></name>
<name><surname>Salgo</surname><given-names>M</given-names></name>
<name><surname>Buss</surname><given-names>N</given-names></name>
<name><surname>Patel</surname><given-names>IH</given-names></name>
</person-group>. <article-title>Population pharmacokinetics and exposure-response relationship of enfuvirtide in treatment-experienced human immunodeficiency virus type 1-infected patients</article-title>. <source>Clin Pharmacol Ther</source>. <year>2005</year>;<volume>77</volume>:<fpage>515</fpage>-<lpage>528</lpage>.</citation>
</ref>
<ref id="bibr12-0091270010388648">
<label>12.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Chakraborty</surname><given-names>A</given-names></name>
<name><surname>Natarajan</surname><given-names>J</given-names></name>
<name><surname>Guilfoyle</surname><given-names>M</given-names></name>
<name><surname>Morgan</surname><given-names>N</given-names></name>
<name><surname>Vercammen</surname><given-names>E</given-names></name>
<name><surname>Cheung</surname><given-names>W</given-names></name>
</person-group>. <article-title>Population pharmacokinetics of erythropoietin in critically ill subjects</article-title>. <source>J Clin Pharmacol</source>. <year>2005</year>;<volume>45</volume>:<fpage>193</fpage>-<lpage>202</lpage>.</citation>
</ref>
<ref id="bibr13-0091270010388648">
<label>13.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Hayashi</surname><given-names>N</given-names></name>
<name><surname>Kinoshita</surname><given-names>H</given-names></name>
<name><surname>Yukawa</surname><given-names>E</given-names></name>
<name><surname>Higuchi</surname><given-names>S</given-names></name>
</person-group>. <article-title>Pharmacokinetic analysis of subcutaneous erythropoietin administration with nonlinear mixed effect model including endogenous production</article-title>. <source>Br J Clin Pharmacol</source>. <year>1998</year>;<volume>46</volume>:<fpage>11</fpage>-<lpage>19</lpage>.</citation>
</ref>
<ref id="bibr14-0091270010388648">
<label>14.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Woo</surname><given-names>S</given-names></name>
<name><surname>Krzyzanski</surname><given-names>W</given-names></name>
<name><surname>Duliege</surname><given-names>AM</given-names></name>
<name><surname>Stead</surname><given-names>RB</given-names></name>
<name><surname>Jusko</surname><given-names>WJ</given-names></name>
</person-group>. <article-title>Population pharmacokinetics and pharmacodynamics of peptidic erythropoiesis receptor agonist (ERA) in healthy volunteers</article-title>. <source>J Clin Pharmacol</source>. <year>2008</year>;<volume>48</volume>:<fpage>43</fpage>-<lpage>52</lpage>.</citation>
</ref>
<ref id="bibr15-0091270010388648">
<label>15.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Troconiz</surname><given-names>IF</given-names></name>
<name><surname>Cendros</surname><given-names>JM</given-names></name>
<name><surname>Peraire</surname><given-names>C</given-names></name>
<etal/></person-group>. <article-title>Population pharmacokinetic analysis of lanreotide Autogel in healthy subjects: evidence for injection interval of up to 2 months</article-title>. <source>Clin Pharmacokinet</source>. <year>2009</year>;<volume>48</volume>:<fpage>51</fpage>-<lpage>62</lpage>.</citation>
</ref>
<ref id="bibr16-0091270010388648">
<label>16.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Zhou</surname><given-names>H</given-names></name>
<name><surname>Chen</surname><given-names>TL</given-names></name>
<name><surname>Marino</surname><given-names>M</given-names></name>
<etal/></person-group>. <article-title>Population PK and PK/PD modelling of microencapsulated octreotide acetate in healthy subjects</article-title>. <source>Br J Clin Pharmacol</source>. <year>2000</year>;<volume>50</volume>:<fpage>543</fpage>-<lpage>552</lpage>.</citation>
</ref>
<ref id="bibr17-0091270010388648">
<label>17.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Glatt</surname><given-names>S</given-names></name>
<name><surname>Fuseau</surname><given-names>E</given-names></name>
<name><surname>Buraglio</surname><given-names>M</given-names></name>
<name><surname>Nguyen</surname><given-names>QT</given-names></name>
</person-group>. <article-title>Population pharmacokinetics of onercept in healthy subjects</article-title>. <source>Clin Pharmacokinet</source>. <year>2005</year>;<volume>44</volume>:<fpage>1295</fpage>-<lpage>1304</lpage>.</citation>
</ref>
<ref id="bibr18-0091270010388648">
<label>18.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Jen</surname><given-names>JF</given-names></name>
<name><surname>Glue</surname><given-names>P</given-names></name>
<name><surname>Ezzet</surname><given-names>F</given-names></name>
<etal/></person-group>. <article-title>Population pharmacokinetic analysis of pegylated interferon alfa-2b and interferon alfa-2b in patients with chronic hepatitis C</article-title>. <source>Clin Pharmacol Ther</source>. <year>2001</year>;<volume>69</volume>:<fpage>407</fpage>-<lpage>421</lpage>.</citation>
</ref>
<ref id="bibr19-0091270010388648">
<label>19.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Nalda-Molina</surname><given-names>R</given-names></name>
<name><surname>Valenzuela</surname><given-names>B</given-names></name>
<name><surname>Ramon-Lopez</surname><given-names>A</given-names></name>
<name><surname>Miguel-Lillo</surname><given-names>B</given-names></name>
<name><surname>Soto-Matos</surname><given-names>A</given-names></name>
<name><surname>Perez-Ruixo</surname><given-names>JJ</given-names></name>
</person-group>. <article-title>Population pharmacokinetics meta-analysis of plitidepsin (Aplidin) in cancer subjects</article-title>. <source>Cancer Chemother Pharmacol</source>. <year>2009</year>;<volume>64</volume>:<fpage>97</fpage>-<lpage>108</lpage>.</citation>
</ref>
<ref id="bibr20-0091270010388648">
<label>20.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Girard</surname><given-names>P</given-names></name>
<name><surname>Nony</surname><given-names>P</given-names></name>
<name><surname>Erhardtsen</surname><given-names>E</given-names></name>
<etal/></person-group>. <article-title>Population pharmacokinetics of recombinant factor VIIa in volunteers anticoagulated with acenocoumarol</article-title>. <source>Thromb Haemost</source>. <year>1998</year>;<volume>80</volume>:<fpage>109</fpage>-<lpage>113</lpage>.</citation>
</ref>
<ref id="bibr21-0091270010388648">
<label>21.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Klitgaard</surname><given-names>T</given-names></name>
<name><surname>Nielsen</surname><given-names>JN</given-names></name>
<name><surname>Skettrup</surname><given-names>MP</given-names></name>
<name><surname>Harper</surname><given-names>A</given-names></name>
<name><surname>Lange</surname><given-names>M</given-names></name>
</person-group>. <article-title>Population pharmacokinetic model for human growth hormone in adult patients in chronic dialysis compared with healthy subjects</article-title>. <source>Growth Horm IGF Res</source>. <year>2009</year>;<volume>19</volume>:<fpage>463</fpage>-<lpage>470</lpage>.</citation>
</ref>
<ref id="bibr22-0091270010388648">
<label>22.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Karlsson</surname><given-names>MO</given-names></name>
<name><surname>Wade</surname><given-names>JR</given-names></name>
<name><surname>Loumaye</surname><given-names>E</given-names></name>
<name><surname>Munafo</surname><given-names>A</given-names></name>
</person-group>. <article-title>The population pharmacokinetics of recombinant- and urinary-human follicle stimulating hormone in women</article-title>. <source>Br J Clin Pharmacol</source>. <year>1998</year>;<volume>45</volume>:<fpage>13</fpage>-<lpage>20</lpage>.</citation>
</ref>
</ref-list>
</back>
</article>